228 related articles for article (PubMed ID: 11036007)
1. Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae.
Jorgensen JH; Weigel LM; Swenson JM; Whitney CG; Ferraro MJ; Tenover FC
Antimicrob Agents Chemother; 2000 Nov; 44(11):2962-8. PubMed ID: 11036007
[TBL] [Abstract][Full Text] [Related]
2. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.
Jorgensen JH; Weigel LM; Ferraro MJ; Swenson JM; Tenover FC
Antimicrob Agents Chemother; 1999 Feb; 43(2):329-34. PubMed ID: 9925527
[TBL] [Abstract][Full Text] [Related]
3. Antipneumococcal activities of gemifloxacin compared to those of nine other agents.
Davies TA; Kelly LM; Pankuch GA; Credito KL; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2000 Feb; 44(2):304-10. PubMed ID: 10639354
[TBL] [Abstract][Full Text] [Related]
4. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
Nagai K; Davies TA; Dewasse BE; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 2001 Sep; 48(3):365-74. PubMed ID: 11533001
[TBL] [Abstract][Full Text] [Related]
5. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
LaPlante KL; Rybak MJ; Tsuji B; Lodise TP; Kaatz GW
Antimicrob Agents Chemother; 2007 Apr; 51(4):1315-20. PubMed ID: 17296740
[TBL] [Abstract][Full Text] [Related]
6. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
[TBL] [Abstract][Full Text] [Related]
7. A comparative In vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across Europe, North America, and South America. The Gemifloxacin Surveillance Study Research Group.
Hoban DJ; Bouchillon SK; Karlowsky JA; Johnson JL; Butler DL; Miller LA; Poupard JA
Antimicrob Agents Chemother; 2000 Nov; 44(11):3008-11. PubMed ID: 11036014
[TBL] [Abstract][Full Text] [Related]
8. Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains.
Heinemann B; Wisplinghoff H; Edmond M; Seifert H
Antimicrob Agents Chemother; 2000 Aug; 44(8):2211-3. PubMed ID: 10898706
[TBL] [Abstract][Full Text] [Related]
9. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
Kosowska-Shick K; Credito K; Pankuch GA; Lin G; Bozdogan B; McGhee P; Dewasse B; Choi DR; Ryu JM; Appelbaum PC
Antimicrob Agents Chemother; 2006 Jun; 50(6):2064-71. PubMed ID: 16723567
[TBL] [Abstract][Full Text] [Related]
10. In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV.
Garrison MW; Schimmels JA; Madaras-Kelly KJ
Diagn Microbiol Infect Dis; 2003 Dec; 47(4):587-93. PubMed ID: 14711480
[TBL] [Abstract][Full Text] [Related]
11. Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin.
Evans ME
Eur J Clin Microbiol Infect Dis; 2001 Dec; 20(12):883-5. PubMed ID: 11837640
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins.
Brisse S; Milatovic D; Fluit AC; Verhoef J; Martin N; Scheuring S; Köhrer K; Schmitz FJ
Antimicrob Agents Chemother; 1999 Aug; 43(8):2051-5. PubMed ID: 10428935
[TBL] [Abstract][Full Text] [Related]
13. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.
Brueggemann AB; Coffman SL; Rhomberg P; Huynh H; Almer L; Nilius A; Flamm R; Doern GV
Antimicrob Agents Chemother; 2002 Mar; 46(3):680-8. PubMed ID: 11850248
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of fluoroquinolones (gatifloxacin, levofloxacin and trovafloxacin) and seven other antibiotics against Streptococcus pneumoniae.
Nicodemo AC; Mendes CM; Oplustil CP; Sinto S
Braz J Infect Dis; 2001 Apr; 5(2):50-2. PubMed ID: 11493408
[TBL] [Abstract][Full Text] [Related]
15. In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae.
Nagai K; Davies TA; Pankuch GA; Dewasse BE; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2000 Oct; 44(10):2740-6. PubMed ID: 10991854
[TBL] [Abstract][Full Text] [Related]
16. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.
Weigel LM; Anderson GJ; Facklam RR; Tenover FC
Antimicrob Agents Chemother; 2001 Dec; 45(12):3517-23. PubMed ID: 11709333
[TBL] [Abstract][Full Text] [Related]
17. Relative potential for selection of quinolone-resistance-determining-region mutations in Streptococcus pneumoniae by gemifloxacin, gatifloxacin and moxifloxacin.
De Azavedo JC; Duncan CL; Kilburn L; Downar J; Kong B; Lad S; Low DE; Bast DJ
J Chemother; 2006 Aug; 18(4):373-8. PubMed ID: 17024792
[TBL] [Abstract][Full Text] [Related]
18. Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.
Hershberger E; Rybak MJ
Antimicrob Agents Chemother; 2000 Mar; 44(3):598-601. PubMed ID: 10681324
[TBL] [Abstract][Full Text] [Related]
19. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
